Answers are grounded in this paper and cite their sources.
Objectives: To evaluate the effectiveness, tolerability, and safety profile of tofacitinib in patients with rheumatoid arthritis. Methodology: A retrospective observational cohort study using routine clinical records from May 2, 2023 to December 31, 2025. Adults meeting the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria were included. Effectiveness was assessed by change in DAS28 disease activity category and by remission or low disease activity at follow-up. Paired category changes used Wilcoxon signed-rank and marginal homogeneity tests. Logistic regression examined predictors of remission. Results: The cohort included 319 patients, mean age 41.23 ± 12.40 years, 71.8% women. Baseline disease activity was high in 87.1% and moderate in 12.9%, with no remission. At follow-up, 47.0% achieved remission and 36.7% achieved low disease activity, while high activity fell to 6.3% with p less than 0.001. Male sex showed lower odds of remission with adjusted odds ratio 0.599 and 95% confidence interval 0.362 to 0.990. Adverse events were documented in 9.4%. Treatment was recorded as well tolerated in 93.7%, and 15.7% discontinued. Common events were raised ALT 6.3%, lipid abnormalities 3.1%, and herpes zoster 3.1%. Myocardial infarction 1.3% and thrombosis 0.9% were rare. Conclusion: In this tertiary-care cohort, tofacitinib was linked to a large shift toward remission or low disease activity with a manageable recorded safety profile. Use requires baseline risk review and follow-up monitoring.
No takes yet. Share an insight, caveat, or question.
Zeb et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: